1. Home
  2. MSD vs NYXH Comparison

MSD vs NYXH Comparison

Compare MSD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Debt Fund Inc.

MSD

Morgan Stanley Emerging Markets Debt Fund Inc.

HOLD

Current Price

$7.24

Market Cap

151.1M

Sector

Finance

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$1.36

Market Cap

126.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSD
NYXH
Founded
1993
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.1M
126.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MSD
NYXH
Price
$7.24
$1.36
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
98.8K
241.9K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
11.26%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$213.98
Revenue Next Year
N/A
$126.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.91
$1.31
52 Week High
$7.94
$8.59

Technical Indicators

Market Signals
Indicator
MSD
NYXH
Relative Strength Index (RSI) 44.04 18.84
Support Level $6.91 N/A
Resistance Level $7.48 $5.02
Average True Range (ATR) 0.10 0.16
MACD -0.01 -0.17
Stochastic Oscillator 25.79 5.03

Price Performance

Historical Comparison
MSD
NYXH

About MSD Morgan Stanley Emerging Markets Debt Fund Inc.

Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: